edoxaban - Articles and news items

Servier Canada to market edoxaban in Canada

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

Edoxaban is an oral anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting…

NICE recommends edoxaban for deep vein thrombosis

Industry news / 26 August 2015 / Victoria White

NICE has recommended once-daily edoxaban for the treatment and prevention of recurrent DVT and pulmonary embolism, saying the drug is cost-effective for the NHS…

Real world ETNA registries of new once-daily edoxaban start in Europe

Industry news / 24 August 2015 / Victoria White

ETNA registries have commenced in Europe to collect a robust set of information on how once-daily edoxaban is being used in real world settings…

Daiichi Sankyo’s edoxaban launched in the UK

Industry news / 10 July 2015 / Victoria White

Edoxaban, a new blood-thinning drug therapy to help prevent stroke in patients with non-valvular atrial fibrillation, has been launched in the UK…

Lixiana

Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation

Industry news / 15 April 2015 / Daiichi Sankyo

Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation…

Daiichi Sankyo logo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk

Industry news, News / 9 January 2015 / Daiichi Sankyo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism…

Daiichi Sankyo logo

Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan

Industry news / 8 December 2014 / Daiichi Sankyo

Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets…

Daiichi Sankyo logo

Once-daily edoxaban evaluated in two subgroup analyses of East Asian patients from the largest comparative phase 3 trials of a novel oral anticoagulant

Industry news / 24 March 2014 / Daiichi Sankyo

Daiichi Sankyo Company, Limited announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies…

Daiichi Sankyo logo

Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA

Industry news / 9 January 2014 / Daiichi Sankyo

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism…

Daiichi Sankyo logo

Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism

Industry news / 8 January 2014 / Daiichi Sankyo

Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation…

Daiichi Sankyo logo

Daiichi Sankyo submits supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for new indications

Industry news / 19 December 2013 / Daiichi Sankyo Company

Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism…

Daiichi Sankyo logo

Phase 3 data show Daiichi Sankyo’s once-daily edoxaban lowered incidence of VTE recurrence and clinically relevant bleeding

Industry news, News / 10 December 2013 / Daiichi Sankyo Company

This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition…

  • Page 1 of 2
  • 1
  • 2
  • >

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+